Evidence map›Paper›PMID 37446361›Full record

ArticleInternational journal of molecular sciences2023

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).

David Pizarro, Ignacio Romero, Belén Pérez-Mies, Andrés Redondo, Tamara Caniego-Casas, Irene Carretero-Barrio, Eva Cristóbal, Ana Gutiérrez-Pecharromán, Ana Santaballa, Emanuela D'Angelo and 9 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 2 countries.

David PizarroPathology Department, University Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Ignacio RomeroInstituto Valenciano de Oncología, 46009 Valencia, Spain.
Belén Pérez-MiesPathology Department, University Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Andrés RedondoSpanish Group for Investigation on Ovarian Cancer (GEICO), 28003 Madrid, Spain.ORCID 0000-0002-7257-5642
Tamara Caniego-CasasPathology Department, University Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Irene Carretero-BarrioPathology Department, University Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0003-1986-2965
Eva CristóbalBiomedical Research Network in Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Ana Gutiérrez-PecharrománPathology Department, University Hospital Getafe, 28905 Getafe, Spain.
Ana SantaballaSpanish Group for Investigation on Ovarian Cancer (GEICO), 28003 Madrid, Spain.
Emanuela D'AngeloDepartment of Medical, Oral, and Biotechnological Sciences, University "G.D'Annunzio" of Chieti-Pescara, 66013 Chieti, Italy.ORCID 0000-0002-6173-1806
David HardissonBiomedical Research Network in Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-2183-3699
Begoña VieitesPathology Department, University Hospital Virgen del Rocío, 41013 Sevilla, Spain.
Xavier Matías-GuiuBiomedical Research Network in Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Purificación EstévezSpanish Group for Investigation on Ovarian Cancer (GEICO), 28003 Madrid, Spain.
Eva GuerraSpanish Group for Investigation on Ovarian Cancer (GEICO), 28003 Madrid, Spain.
Jaime PratPathology Department, Emeritus Faculty, Autonomous University of Barcelona, 08193 Barcelona, Spain.
Andrés PovedaSpanish Group for Investigation on Ovarian Cancer (GEICO), 28003 Madrid, Spain.
José Antonio López-GuerreroInstituto Valenciano de Oncología, 46009 Valencia, Spain.ORCID 0000-0002-7369-8388
José PalaciosPathology Department, University Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-6730-5066
Universidad de Alcalá · ESFundación Instituto Valenciano de Oncología · ESHospital Universitario La Paz · ESInstituto de Salud Carlos III · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESHospital Quirónsalud Barcelona · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de Getafe · ESHospital Universitario Virgen del Rocío · ESInstituto de Biomedicina de Sevilla · ESUniversitat Autònoma de Barcelona · ESUniversitat de Lleida · ESUniversity of Chieti-Pescara · IT

Funding

Asociación Española Contra el Cáncer NACentro de Investigación Biomédica en Red de Cáncer CB16/12/00316Instituto de Salud Carlos III PI19/01331Instituto de Salud Carlos III PI22/01892Instituto de Salud Carlos III PMP22/00054Spanish Ovarian Cancer Research Group NA
6 · The paper itself

Abstract

Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression,

Indexed as

Lymphocytes, Tumor-InfiltratingOvarian NeoplasmsB7-H1 AntigenFemaleHumansMutationPrognosisRetrospective StudiesB7-H1 AntigenBRCAearly stagehigh-grade serous ovarian carcinomaPD-L1TMB

Identifiers

PMID37446361
PMCPMC10342764
OpenAlexW4383551088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.